← Leaderboards
Carolyn Sue Richards
Kaiser Foundation Research Institute
$1,195,647
Attributed
$2,391,294
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $667.2K · FY2011–14$1M$750K$500K$250K$0
'11
'12
'13
'14
Funding mix
By agency
NIH$2,391,294 · 1
By mechanism
R01$2,391,294 · 1
Top collaborators
- Sheila A Weinmann4 shared
Most similar at Kaiser Foundation Research Institute
Same institution · by research overlap
- Andrew John Karter$16,048,581
- Lynn Larson Debar$40,780,655
- Lawrence H Kushi$60,993,337
- Lisa A Jackson$41,789,727
- Victor J Stevens$20,387,228
Others in their field
Top investigators on “Adjuvant”
- Lawrence Corey · Fred Hutchinson Cancer Center$377,142,999
- Norman Wolmark · Nsabp Foundation, Inc.$267,141,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$167,183,168
- David Heimbrook · Leidos Biomedical Research, Inc.$151,668,128
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$131,206,481
- Peter B. Gilbert · Fred Hutchinson Cancer Center$117,668,001
Research focus
AdjuvantAdjuvant TherapyAdverse EffectsAffectAllelesAromatase InhibitorsBaseBiobankBioinformaticsBreast Cancer TreatmentCancer RecurrenceCancer TherapyCase-Control StudiesCategoriesCaucasiansCaucasoid RaceCessation Of LifeCharacteristicsClassificationClinical TrialsCollaborationsComputerized Medical RecordCyp2d6 GeneAdherence (Attribute)
Grant awards (4)
CYP2D6 gene variants and effectiveness of adjuvant tamoxifen in breast cancer$575,924
R01 · FY2014 · CA
CYP2D6 gene variants and effectiveness of adjuvant tamoxifen in breast cancer$534,276
R01 · FY2013 · CA
CYP2D6 gene variants and effectiveness of adjuvant tamoxifen in breast cancer$613,849
R01 · FY2012 · CA
CYP2D6 gene variants and effectiveness of adjuvant tamoxifen in breast cancer$667,245
R01 · FY2011 · CA